Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Young Hodgkin Lymphoma Survivors Often Don’t Receive Recommended Care

January 14, 2016
By Dave Levitan
News
Article

Most adolescent and young adult survivors of Hodgkin lymphoma did not receive the recommended care within the first year post-treatment, according to a study.

Most adolescent and young adult (AYA) survivors of Hodgkin lymphoma did not receive the recommended care within the first year post-treatment, according to a study. The results were presented at the American Society of Clinical Oncology (ASCO) Cancer Survivorship Symposium held in San Francisco.

“AYAs who are diagnosed and treated for Hodgkin lymphoma have very high overall survival rates, which is fantastic,” said lead study author Erin E. Hahn, PhD, MPH, of Kaiser Permanente Southern California, during a press call in advance of the symposium. “However, they are at high risk for both short- and long-term health issues related to their cancer treatment.”

The National Comprehensive Cancer Network (NCCN) offers guidelines on post-treatment care, and this study examined adherence to those guidelines in 354 AYA survivors.

In terms of short-term care, most patients received recommended visits, lab tests, and imaging in the first year, while less than half of patients received the flu vaccine, a recommended preventive care treatment. A composite measure of all the first-year recommended items showed that only 48% of survivors received all of them.

Almost all patients (96%) had recommended oncology visits within the first 5 years, and 70% received recommended lab tests. About two-thirds of the patients received a recommended CT scan in the first year, but 47% received CT scans in years 2 and 3, which are not actually recommended by NCCN.

Looking specifically at a high-risk group of patients who were initially treated with high-dose anthracyclines, cardiac screening more than 10 years out is recommended. Among 56 such patients, almost all underwent annual blood pressure screening, but only 30% received echocardiograms and other screening modalities.

The year of diagnosis was significantly associated with receipt of recommended care, with those diagnosed between 2000 and 2005 less likely to receive the care than those diagnosed from 2006 to 2010 (P < .0001).

“This study really shows that there is a need to improve care delivery for these patients,” Hahn said, adding that there is clear opportunity to design and implement systematic programs to address these gaps in care.

Merry-Jennifer Markham, MD, of the University of Florida College of Medicine and an ASCO expert who was not involved with the study, agreed that the opportunity to improve is obvious. “Most of them will have long lives ahead of them,” she said. “Despite the guidelines, Dr. Hahn’s study illustrates that less than half…are receiving some critical components of survivorship care.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Related Content

No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.

Tuspetinib Exhibits Enhanced Efficacy in Diverse Newly Diagnosed AML Group

Roman Fabbricatore
August 19th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 19th 2025
Podcast

Jose Sandoval Sus, MD, discussed the “revolution” that CAR T-cell therapies have facilitated for patients with large B-cell lymphomas.

Considerations for CAR T Use Across Large B-Cell Lymphoma Variants

Roman Fabbricatore
August 19th 2025
Article

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
August 19th 2025
Podcast

Pre-planned interim results from the phase 3 EPCORE FL-1 trial supported the FDA granting priority review to epcoritamab with rituximab and lenalidomide in relapsed/refractory FL.

SC Epcoritamab Combo Meets ORR/PFS End Points in R/R Follicular Lymphoma

Tim Cortese
August 19th 2025
Article

The CAR-T yielded a manageable safety profile in patients with mantle cell lymphoma.

Novel Treatment Receives FDA RMAT Designation in R/R Mantle Cell Lymphoma

Tim Cortese
August 19th 2025
Article
Related Content

No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.

Tuspetinib Exhibits Enhanced Efficacy in Diverse Newly Diagnosed AML Group

Roman Fabbricatore
August 19th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 19th 2025
Podcast

Jose Sandoval Sus, MD, discussed the “revolution” that CAR T-cell therapies have facilitated for patients with large B-cell lymphomas.

Considerations for CAR T Use Across Large B-Cell Lymphoma Variants

Roman Fabbricatore
August 19th 2025
Article

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
August 19th 2025
Podcast

Pre-planned interim results from the phase 3 EPCORE FL-1 trial supported the FDA granting priority review to epcoritamab with rituximab and lenalidomide in relapsed/refractory FL.

SC Epcoritamab Combo Meets ORR/PFS End Points in R/R Follicular Lymphoma

Tim Cortese
August 19th 2025
Article

The CAR-T yielded a manageable safety profile in patients with mantle cell lymphoma.

Novel Treatment Receives FDA RMAT Designation in R/R Mantle Cell Lymphoma

Tim Cortese
August 19th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.